CELA3A: A Potential Drug Target and Biomarker (G10136)

Target Name: CELA3A

NCBI ID: G10136

CELA3A

CELA3A: A Potential Drug Target and Biomarker

CELA3A is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is CELA3A, and it is a member of the Calbindin family of proteins. Calbindin is a widely expressed protein that is involved in a variety of cellular processes, including cell signaling, cytoskeletal organization, and neurotransmitter release. CELA3A, with its unique expression pattern and function, has been identified as a potential drug target and biomarker.

The CELA3A protein is expressed in the brain and other tissues, and its levels have been shown to be elevated in individuals with various neurological disorders, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Additionally, CELA3A has been shown to be involved in neurotransmitter release, which is critical for the function of neurons and the development of neurotransmitter-related disorders.

CELA3A has also been shown to play a role in the regulation of pain perception and neuroinflammation. Chronic pain is a prevalent condition that can have a significant impact on an individual's quality of life, and research has suggested that CELA3A may be involved in the development and treatment of chronic pain.

In addition to its potential role in neurological disorders, CELA3A has also been shown to be involved in the development and progression of certain diseases. For example, CELA3A has been shown to be expressed in the lungs of individuals with chronic obstructive pulmonary disease (COPD), and increased levels of CELA3A have been associated with the development of COPD in animal models. Similarly, CELA3A has been shown to be involved in the development and progression of cancer, with increased levels of CELA3A being observed in various types of cancer.

Despite its potential as a drug target and biomarker, much more research is needed to fully understand the role of CELA3A in various biological processes. For example, it is unclear whether modulating CELA3A levels or activity can be a effective way to treat neurological disorders or diseases. Additionally, the development of CELA3A-targeted therapies may also have potential ethical implications, as the use of certain drugs that target this protein may raise concerns about potential harm to individuals.

In conclusion, CELA3A is a protein that has been identified as a potential drug target and biomarker. Its unique expression pattern and function in various tissues make it an attractive target for further research, with the potential to contribute to the development of new treatments for a variety of neurological disorders and diseases.

Protein Name: Chymotrypsin Like Elastase 3A

Functions: Efficient protease with alanine specificity but only little elastolytic activity

The "CELA3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CELA3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets